Incorporated in 1988, Alpa Laboratories Ltd manufactures and sells Drugs and Chemicals
The company operates as a generic pharmaceutical manufacturer with no identifiable mechanism for pricing power or cost advantage, as evidenced by a low average ROCE of 8.7% and stagnant revenue growth. While they possess regulatory licenses, these are table stakes in the industry and do not translate into a durable competitive edge or superior returns on capital.
Management has prioritized liquidity and conservative reinvestment, maintaining a near-zero debt profile. However, the decision to halt dividends to fund a land purchase in Pithampur suggests a shift toward capacity expansion despite historically mediocre returns on equity (6.2%).
Five years out, the capital allocated to the Pithampur land purchase has proven to be a value-destructive trap. By prioritizing physical expansion in a commoditized market where the company lacks pricing power, management effectively buried shareholder capital in low-yield assets while revenue growth remained stagnant. The persistent gap between reported profits and actual cash flow eventually forced a write-down of receivables, and the unresolved tax litigations from decades prior culminated in a massive cash outflow, leaving the company as a stagnant, cash-poor shell of its former self.
RichFakir rates Alpa Laboratories Ltd's business quality as mediocre — 47/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Alpa Laboratories Ltd is trading about 41% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Alpa Laboratories Ltd is: Not rated. A mediocre business at a cheap price — it does not make our shortlist right now.
RichFakir's educational estimate of Alpa Laboratories Ltd's fair value is about ₹86 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →